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Sweet syndrome is an increasingly recognized disease be-
longing to the spectrum of neutrophilic dermatosis. It may be 
classical, malignancy-associated or drug-induced.
A 57-year-old female was admitted for acute intracerebral 
hemorrhage. Her medical history included epilepsy, intracere-
bral hemorrhage 9 years before, hypertension, dyslipidaemia, 
diabetes mellitus type 2 and depression. Two days following 
admission, carbamazepine 400 mg twice daily was initiated 
for epilepsy. After five days, she developed multiple erythema-
tous round painless papules and plaques on dorsum of both 
hands and malar regions, some of them with local bullae and 
others with target-like appearance (Fig. 1A-C), with no mu-
cous involvement. No fever or other systemic signs were re-
gistered. The unique medication introduced in the previous 6 
months was carbamazepine, whose levels were 14.40 ug/mL 
(NR 4.00-12.00) when the dermatosis initiated. There was no 
leukocytosis/neutrophilia but a C-reactive protein of 80 mg/L 
(N<3.0). A cutaneous biopsy on a dorsal hand lesion yielded 
an acanthotic ulcerated epidermis and a neutrophilic inflam-
matory infiltrate with leukocytoclasia in the dermis (Fig. 2A-C), 
but no signs of vasculitis. Bacteriological swab of an ulcerated 
lesion was negative, as well as bacteriological, mycobacterio-
logical and mycological examination of the cutaneous biopsy.
Based on suspicion of drug-induced Sweet syndrome, car-
bamazepine was stopped once the dermatosis started. Oral 
prednisolone was initiated at a dose of 0.5 mmg per kilogram 
for 5 days, with a slow gradual tapering during the following 
30 days. The patient evolved with complete remission of the 
lesions in 7 days, without recurrence after 6 months of follow-
-up. Epilepsy is currently under control with levetiracetam and 
there was no need to reintroduce carbamazepine. According 
to Naranjo’s method for estimating the probability of adverse 
drug reactions1, Sweet Syndrome in this specific case was pro-
bably induced by carbamazepine (6 points).
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In order to diagnose a drug-induced Sweet syndrome, 
specific unique diagnostic criteria should be found, mainly 
the temporal relationship between drug ingestion and clini-
cal presentation, as well as temporally-related resolution of 
lesions after treatment with systemic corticosteroids. The di-
sease may recur after drug readministration. Multiple drugs 
have been implicated in Sweet syndrome, mainly colony-
-stimulating factors, all-trans retinoic acid, vaccines and 
miscellaneous drugs.2 Carbamazepine is also known to be 
a possible trigger, sometimes with bullous presentation, as 
shown in several large series of drug-induced Sweet syndro-
me.3,4 However, it may be considered an uncommon cause, 
since some series did not find any case induced by carba-
mazepine.5
With this case report, we highlight the difficulty of clinical 
and histopathological evaluation of cutaneous lesions in a pa-
tient with multiple co morbidities and provide a new case of 
carbamazepine-induced Sweet syndrome. This iatrogenic di-
sease may have substantial impact on the therapeutic options 
of epileptic patients.
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Figure 2A-C - Histopathological features showing a dense infiltra-
te of mature neutrophils in the upper dermis and reactive changes of 
epidermis (A, hematoxylin-eosin stained slide, 40x); Highlight of the 
dermis with dense infiltrate of mature neutrophils (B, hematoxylin-eosin 
stained slide, 200x); Highlight of leukocytoclasia, with nuclear dust (C, 
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